• About PAH

• About Ventavis

•      Indications

•      Efficacy

•           Clinical Improvement

•           Improved Exercise
            Capacity

•           Functional Class
            Improvement

•           Improved
            Hemodynamics

•      Safety Profile

•      Dosage & Administration

•      Ventavis AirTime

•      FAQs

•      Ventavis Support

• About the I-neb AAD
  System

• Services for Your Patients

• Resources

• Prescribing Information

• For Patients and
  Caregivers

Clinical Trials

The composite primary endpoint was clinical response at 12 weeks, defined as:

1. At least 10% increase vs. baseline in 6-minute walk distance¹
2. Improvement by at least one NYHA Class vs. baseline^1,2
3. Lack of clinical deterioration or death

Studied as combination therapy

• In a small study, 34 patients treated with bosentan 125 mg bid for at least 16 weeks tolerated the addition of inhaled iloprost (up to 5 mcg 6 to 9 times per day during waking hours). The mean daily inhaled dose was 27 mcg and the mean number of inhalations per day was 5.6.²
• Safety trends in patients receiving concomitant bosentan and iloprost were consistent with those observed in the larger Phase 3 study (AIR) in patients receiving only iloprost.²

1. Ventavis (iloprost) Full Prescribing Information. Actelion Pharmaceuticals US, Inc. 2009.
2. Olschewski H, Simonneau G, Galie N et al, for the Aerosolized Iloprost Randomized Study Group. Inhaled iloprost for severe pulmonary hypertension. N Engl J Med. 2002;347:322-329.

For more information about
Ventavis, please call
1-866-ACTELION (1-866-228-3546).